1. Introduction {#sec1}
===============

Ankylosing spondylitis (AS) is a chronic inflammatory disease of the axial skeleton, also associated with peripheral arthritis and cardiac, ocular, and gastrointestinal manifestations.

Cardiovascular mortality has been found to be increased in rheumatic diseases, which is attributed to accelerated atherosclerosis \[[@B1], [@B2]\]. A wide range of cardiovascular features are associated with ankylosing spondylitis, namely, aortitis, aortic regurgitation, and conduction abnormalities \[[@B3], [@B4]\], along with an increased risk of atherosclerosis related cardiovascular events like myocardial infarction and stroke, leading to a significantly increased mortality \[[@B5], [@B6]\]. Chronic systemic inflammation is implicated as the driving force behind accelerated atherosclerosis in rheumatic diseases \[[@B7], [@B8]\].

Among the various screening methods, carotid intima media thickness (CIMT) has gained wide acceptance as a marker of atherosclerosis predicting future cardiovascular events \[[@B9], [@B10]\].

In this study we have compared CIMT in patients of AS with a matched group of healthy individuals. We also studied the correlation between CIMT and Bath ankylosing spondylitis disease activity index (BASDAI), Bath ankylosing spondylitis functional index (BASFI), and Bath ankylosing spondylitis metrological index (BASMI) scores and C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) and HLA B-27 status.

2. Methods {#sec2}
==========

Thirty-seven patients were recruited from the rheumatology clinic at Sawai Man Singh Hospital, Jaipur, for the study. The same number of healthy individuals matched for age and sex was recruited from the staff of the hospital. Exclusion criteria for both groups were diabetes mellitus, chronic kidney disease, myocardial infarction, hypertension, family history of premature symptomatic coronary heart disease (\<55 yrs for males; \<65 yrs for females), tobacco chewing, and smoking. Written well-informed consents were obtained from participants of both groups. Necessary clearances were obtained from the institutional ethics committee.

2.1. Clinical Assessment {#sec2.1}
------------------------

From each participant detailed history was taken and BASDAI, BASFI, and BASMI score were calculated from the questionnaire and physical examination.

2.2. Laboratory Evaluation {#sec2.2}
--------------------------

Fasting venous samples of the patients were collected and evaluated for glucose, creatinine, ESR, CRP, lipid profile, and HLA B-27 status. ESR was measured using Westergren method, C-reactive protein by nephelometry, and lipid profile by colorimetry and the presence of HLA B-27 was tested using polymerase chain reaction (PCR) technique.

2.3. CIMT Measurements \[[@B10]\] {#sec2.3}
---------------------------------

CIMT measurements of both study groups were done. All measurements were made by a single examiner. Examination was done in a quiet, cool room (20--25°C). A high resolution B-mode ultrasonography with a 7.5 MHz transducer was used to make the measurements. The subject was placed in supine position with the neck extended and the chin turned contralateral to the side being examined. The distance between the leading edge of the first bright line (the lumen-intima interface) of the far wall and the leading edge of the second bright line (collagen-containing upper layer of tunica adventitia) was taken as the IMT. IMT was measured at three points on the far walls of both the left and the right common carotid arteries (CCA) 10 mm proximal to the carotid bulb. The IMT of these three locations was then averaged to produce the mean IMT for each side. The mean of IMT of each side was taken as the final CIMT.

2.4. Statistical Analysis {#sec2.4}
-------------------------

All measurements were reported as mean ± SD. Chi-square test and Student\'s*t*-test were used to find the significance among various variables. Correlation between quantitative variables was obtained by calculating Pearson\'s correlation coefficient. Statistical significance was considered when *P* \< 0.05.

3. Results {#sec3}
==========

Mean age of the study groups was 29.43 ± 9.00 years. Average disease duration was 65.62 ± 54.92 months. Twenty-eight (75.68%) cases were HLA B-27 positive. We observed a significantly increased CIMT in cases as compared to the control group (0.62 ± 0.12 versus 0.54 ± 0.04; *P* \< 0.001). Serum low density lipoprotein cholesterol (LDL-C) was observed to be significantly lower in the cases as compared to control group (80.96 ± 21.66 versus 107.36 ± 25.84 mg/dL; *P* \< 0.001). No significant difference was observed in levels of triglycerides (TG) and high density lipoprotein cholesterol (HDL-C) in the two groups ([Table 1](#tab1){ref-type="table"}).

CIMT in the cases positively correlated with age (*r* = +0.357; *P* \< 0.05), duration of disease (*r* = +0.549; *P* \< 0.01), and BASMI (*r* = +0.337; *P* \< 0.05). CIMT negatively correlated with cervical rotation (CR) (*r* = −0.296; *P* \< 0.05), lateral flexion (LF) (*r* = −0.344; *P* \< 0.05), intermalleolar distance (IMD) (*r* = −0.268; *P* \< 0.05), lumbar flexion (*r* = −0.313; *P* \< 0.05), and ESR (*r* = −0.295; *P* \< 0.05). No significant correlation was observed between CIMT and age at onset of disease, BASDAI, BASFI, tragus-to-wall (TTW) distance, CRP, and HLA B-27 positivity. No significant correlation was observed between CIMT and HDL-C, LDL-C, and TG levels ([Table 2](#tab2){ref-type="table"}).

4. Discussion {#sec4}
=============

The threat of increased cardiovascular morbidity and mortality in AS and other rheumatic diseases, coupled with the possibility of CIMT measurements to reliably, noninvasively, and inexpensively screen it at a relatively nascent stage, prompted us to go for this study.

Today there is widespread acceptance of CIMT as a reliable and easily reproducible marker of preclinical atherosclerosis and future CVD risk \[[@B10]\].

Tyrrell et al. did a systematic review and meta-analysis of 60 such studies encompassing the entire spectrum of rheumatic diseases and observed a significantly increased CIMT in these patients as compared to matched healthy individuals \[[@B11]\].

In our study, we observed a significant increase in CIMT in patients of AS (0.62 ± 0.12 mm) as compared to the matched group (0.54 ± 0.04 mm) (*P* \< 0.001). These findings echo the observations of other authors all of whom had observed similar increases in CIMT \[[@B12]--[@B18]\].

Other studies also observed an increase of CIMT in AS cases as against the comparison group, but it was not statistically significant \[[@B19]--[@B22]\]. Nonetheless, a meta-analysis by Mathieu et al., studying 6 studies on CIMT in AS, concluded that there was a significant increase in CIMT in AS when compared with matched controls \[[@B21]\].

The findings of our study assume added significance because we excluded the other major risk factors of atherosclerosis, namely, diabetes mellitus, hypertension, chronic kidney disease, past or family history of premature myocardial infarction, and smoking, from our study and control group. Also we observed a statistically significant difference in CIMT while studying a much younger population (mean age 29.43 ± 9.00 years), as compared to Cece et al. \[[@B12]\] (36.8 ± 9.8), Hamdi et al. \[[@B13]\] (36 ± 11), Skare et al. \[[@B15]\] (42.89 ± 11.70), Peters et al. \[[@B17]\] (39), and Mathieu et al. \[[@B21]\] (40).

Choe et al. \[[@B20]\] had a study group with age comparable to ours (31.8 ± 6.8), but they did not observe a significant difference. Cardiovascular affection in inflammatory arthritis has been very commonly observed because of chronic inflammation being a common thread between rheumatology and preventive cardiology \[[@B7]\]. In light of the evidence before us it will be prudent to further evaluate CIMT in larger studies, as a small sample size remains a drawback of all these studies including ours.

In our study LDL-C was significantly lower in cases (*P* \< 0.05). TG was observed to be lower and HDL-C higher in the study group, but this was not statistically significant (*P* \> 0.05). Mathieu et al. \[[@B21]\], in a systematic review and meta-analysis of CVD risk in AS, noted a decrease in TG, LDL-C, and HDL-C levels. Divecha et al. \[[@B23]\] also observed lower levels of total cholesterol and HDL-C in AS. Malesci et al. \[[@B19]\] had observed LDL-C to be significantly higher (*P* = 0.03) and HDL-C significantly lower (*P* \< 0.001) in patients of AS when compared to controls. The paradox of a seemingly beneficial lipid profile predisposing to accelerated atherosclerosis is seen in rheumatoid arthritis (RA) as well. The mechanism behind it is the ability of chronic inflammation to induce changes in the structural composition of the lipid molecules, making them more atherogenic \[[@B24]\]. Chronic inflammation also has the ability to induce endothelial cell dysfunction, wherein there is increased expression of leukocyte adhesion and signalling molecules on their surface. These changes are brought about by a complex interplay of inflammatory cytokines such as IL-6 and TNF-*α*, lipid molecules, and the endothelial cells \[[@B25]\].

In our study we also analyse the correlation of CIMT with markers of disease chronicity and activity in AS. CIMT was found to be positively correlated with age of the patient. We observed CIMT to increase with higher age at onset of disease, but the correlation was not statistically significant. In contrast, a strong correlation between these two parameters was observed in one previous study \[[@B13]\] (*P* = 0.001). We observed that CIMT positively correlated with disease duration ([Table 2](#tab2){ref-type="table"}); in contrast some authors did not observe any significant correlation of CIMT and disease duration \[[@B12], [@B15]--[@B17]\].

CIMT positively correlated with decreased spinal mobility, measured using BASMI scores, consistent with the findings of other authors \[[@B13], [@B16], [@B22]\] while being in variance to some authors \[[@B12], [@B17]\].

In our study no correlation was observed between CIMT and BASDAI and BASFI scores, which concurs with some studies \[[@B15], [@B17], [@B22]\] and differs from some studies \[[@B13], [@B16], [@B20]\].

BASDAI and BASFI scores are the most extensively used scoring systems to make a clinical assessment of disease activity. But it must be pointed out that they suffer from an element of subjectivity as they take into account only the patient\'s perception of his/her disease burden. Also, BASDAI and BASFI scores indicate the inflammatory activity at the time of assessment. They do not tell us about the inflammatory burden of the entire disease duration. On the other hand, the metrological measurements provide us with an objective assessment of the degree of damage that the axial skeleton has to suffer during the entire disease process. Hence, they can be thought of as surrogate markers of disease chronicity. The correlation of disease duration and metrological measurements with CIMT can be explained by the fact that it is chronic systemic inflammation which is driving atherosclerosis in these patients.

No correlation was observed between CIMT and TG, HDL-C, and LDL-C. Similarly, no correlation was observed between CIMT and CRP levels in patients of AS. This can be explained by the fact that unlike RA, CRP is not a good marker of disease activity in AS. It is positive only in 50--60% of cases of AS and correlates poorly with disease activity \[[@B26]\]. Skare et al. \[[@B15]\] and Peters et al. \[[@B17]\] had also made similar observations.

A negative correlation was observed between CIMT and ESR (*r* = −0.295; *P* \< 0.05). A plausible explanation for the same might be that ESR levels are an indicator of the present level of disease activity and do not show the inflammatory burden which has built up over time. This finding, otherwise, cannot be fully explained. A positive correlation between CIMT and ESR was observed in only one study \[[@B13]\].

Out of the 37 cases studied, 28 (75.68%) were positive for HLA B-27 and 9 (24.32%) were negative. Increase in CIMT was not found to be associated with HLA B-27 positivity in our study, the same as in other studies \[[@B13], [@B15]\].

5. Conclusion {#sec5}
=============

Increased CIMT was observed in the present study in patients of AS as compared to normal subjects and it correlated with the BASMI, an index of chronicity of disease.
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###### 

Characteristics of study subjects.

                              Cases of AS (37)       Healthy controls (37)   *P*
  --------------------------- ---------------------- ----------------------- ---------
  Age (range) (years)         29.43 ± 9.0 (17--50)   29.43 ± 9.0 (17--50)    \>0.05
  Age at onset (years)        24.01 ± 8.36           ---                      
  Disease duration (months)   65.62 ± 54.92          ---                      
  BASDAI                      4.11 ± 1.99            ---                      
  BASFI                       4.13 ± 2.09            ---                      
  BASMI                       3.14 ± 2.14            ---                      
  ESR (mm/hr)                 45.19 ± 26.04          ---                      
  CRP (mg/dL)                 7.36 ± 3.78            ---                      
  HLA-B27 (% of cases)        75.68                                           
  CIMT (mm)                   0.62 ± 0.12            0.54 ± 0.04             \<0.001
  TG (mg/dL)                  93.65 ± 36.18          108.62 ± 41.52          \>0.05
  HDL-c (mg/dL)               47.92 ± 6.44           44.92 ± 3.86            \>0.05
  LDL-c (mg/dL)               80.96 ± 21.66          107.36 ± 25.84          \<0.001

###### 

Correlation of CIMT with markers of disease severity and chronicity.

                                 Correlation coefficient (*r*)   *P*
  ------------------------------ ------------------------------- ------------
  CIMT and age                   +0.357                          **\<0.05**
  CIMT and disease duration      +0.549                          **\<0.01**
  CIMT and age at onset          +0.086                          \>0.05
  CIMT and BASDAI                −0.160                          \>0.05
  CIMT and BASFI                 +0.059                          \>0.05
  CIMT and TTW                   +0.098                          \>0.05
  CIMT and lateral flexion       −0.344                          **\<0.05**
  CIMT and IMD                   −0.268                          **\<0.05**
  CIMT and CR                    −0.296                          **\<0.05**
  CIMT and lumbar flexion        −0.313                          **\<0.05**
  CIMT and BASMI                 +0.337                          **\<0.05**
  CIMT and ESR                   −0.295                          **\<0.05**
  CIMT and CRP                   −0.133                          \>0.05
  CIMT and TG                    −0.024                          \>0.05
  CIMT and HDLc                  +0.106                          \>0.05
  CIMT and LDLc                  +0.189                          \>0.05
  CIMT and HLA B-27 positivity   ---                             \>0.05
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